ES2571441A1 - Uso de moléculas que reducen los niveles de lipocalina-2 para la fabricación de un medicamento para el tratamiento de aneurisma aórtico abdominal (AAA) - Google Patents

Uso de moléculas que reducen los niveles de lipocalina-2 para la fabricación de un medicamento para el tratamiento de aneurisma aórtico abdominal (AAA)

Info

Publication number
ES2571441A1
ES2571441A1 ES201431737A ES201431737A ES2571441A1 ES 2571441 A1 ES2571441 A1 ES 2571441A1 ES 201431737 A ES201431737 A ES 201431737A ES 201431737 A ES201431737 A ES 201431737A ES 2571441 A1 ES2571441 A1 ES 2571441A1
Authority
ES
Spain
Prior art keywords
lipocalin
manufacture
treatment
aortic aneurysm
abdominal aortic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
ES201431737A
Other languages
English (en)
Other versions
ES2571441B1 (es
Inventor
Cerezo Carlos Antonio Tarin
Ipiens Elena Burillo
Granda Patricia Llamas
Vargas Carlos Pastor
Colio Luis Miguel Blanco
De Los Rios Jesús Egido
Ventura José Luis Martin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universidad Autonoma de Madrid
Instituto de Investigacion Sanitaria Fundacion Jimenez Diaz
Original Assignee
Universidad Autonoma de Madrid
Instituto de Investigacion Sanitaria Fundacion Jimenez Diaz
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universidad Autonoma de Madrid, Instituto de Investigacion Sanitaria Fundacion Jimenez Diaz filed Critical Universidad Autonoma de Madrid
Priority to ES201431737A priority Critical patent/ES2571441B1/es
Publication of ES2571441A1 publication Critical patent/ES2571441A1/es
Application granted granted Critical
Publication of ES2571441B1 publication Critical patent/ES2571441B1/es
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Uso de moléculas que reducen los niveles de lipocalina-2 para la fabricación de un medicamento para el tratamiento de aneurisma aórtico abdominal (AAA). Uso de un anticuerpo capaz de unirse a lipocalina-2 para la fabricación de un medicamento para el tratamiento de aneurisma aórtico abdominal. Uso de una molécula de ácido nucleico antisentido capaz de inhibir la expresión del gen de lipocalina-2 para la fabricación de un medicamento para el tratamiento de aneurisma aórtico abdominal.
ES201431737A 2014-11-24 2014-11-24 Uso de moléculas que reducen los niveles de lipocalina-2 para la fabricación de un medicamento para el tratamiento de aneurisma aórtico abdominal (AAA) Expired - Fee Related ES2571441B1 (es)

Priority Applications (1)

Application Number Priority Date Filing Date Title
ES201431737A ES2571441B1 (es) 2014-11-24 2014-11-24 Uso de moléculas que reducen los niveles de lipocalina-2 para la fabricación de un medicamento para el tratamiento de aneurisma aórtico abdominal (AAA)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES201431737A ES2571441B1 (es) 2014-11-24 2014-11-24 Uso de moléculas que reducen los niveles de lipocalina-2 para la fabricación de un medicamento para el tratamiento de aneurisma aórtico abdominal (AAA)

Publications (2)

Publication Number Publication Date
ES2571441A1 true ES2571441A1 (es) 2016-05-25
ES2571441B1 ES2571441B1 (es) 2017-03-07

Family

ID=56011713

Family Applications (1)

Application Number Title Priority Date Filing Date
ES201431737A Expired - Fee Related ES2571441B1 (es) 2014-11-24 2014-11-24 Uso de moléculas que reducen los niveles de lipocalina-2 para la fabricación de un medicamento para el tratamiento de aneurisma aórtico abdominal (AAA)

Country Status (1)

Country Link
ES (1) ES2571441B1 (es)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107860926A (zh) * 2017-09-29 2018-03-30 北京市心肺血管疾病研究所 一组检测主动脉瘤/主动脉夹层的血清标志物及其应用
CN109553682A (zh) * 2018-12-29 2019-04-02 江苏众红生物工程创药研究院有限公司 抗人中性粒细胞明胶酶相关脂质运载蛋白抗体及其在检测试纸卡中的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010127294A2 (en) * 2009-05-01 2010-11-04 Abbott Laboratories Dual variable domain immunoglobulins and uses thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010127294A2 (en) * 2009-05-01 2010-11-04 Abbott Laboratories Dual variable domain immunoglobulins and uses thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
RAMOS-MOZO PRISCILA et al. Increased plasma levels of NGAL, a marker of neutrophil activation, in patients with abdominal aortic aneurysm.ATHEROSCLEROSIS 2012. VOL: 220 No: 2 Pags: 552 - 556 ISSN 0021-9150 Doi: doi:10.1016/j.atherosclerosis.2011.11.023 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107860926A (zh) * 2017-09-29 2018-03-30 北京市心肺血管疾病研究所 一组检测主动脉瘤/主动脉夹层的血清标志物及其应用
CN109553682A (zh) * 2018-12-29 2019-04-02 江苏众红生物工程创药研究院有限公司 抗人中性粒细胞明胶酶相关脂质运载蛋白抗体及其在检测试纸卡中的应用
CN109553682B (zh) * 2018-12-29 2022-04-05 江苏众红生物工程创药研究院有限公司 抗人中性粒细胞明胶酶相关脂质运载蛋白抗体及其在检测试纸卡中的应用

Also Published As

Publication number Publication date
ES2571441B1 (es) 2017-03-07

Similar Documents

Publication Publication Date Title
MX2020003995A (es) Nuevas moleculas de acido nucleico artificiales.
BR112016020112A2 (pt) anticorpos multiespecíficos, método para a preparação de um anticorpo multiespecífico, ácido nucleico, vetor de expressão e composição farmacêutica
MX2016013689A (es) Compuestos 4-amino-imidazoquinolina.
HRP20181872T1 (hr) Derivati tamoksifena za liječenje neoplastičnih bolesti, posebice s višom razinom proteina her2
MX2017007641A (es) Conjugados de anticuerpo-farmaco con inhibidores de bcl-xl permeables en las celulas.
EA201690881A1 (ru) Соединения-ингибиторы аутотаксина
EA201791420A1 (ru) Соединения триазолопиримидина и их применения
UA116648C2 (uk) Фумарати як проліки та їх застосування при лікуванні різних захворювань
EA201790785A1 (ru) Производные тетрагидроизохинолина
MX2016010571A (es) Pirazolil-ureas como inhibidores de quinasas.
SA518391864B1 (ar) مشتقات باي بيرازوليل مفيدة لمعالجة أمراض المناعة الذاتية
PH12016501830A1 (en) Inhibitors of c5a for the treatment of viral pneumonia
NZ732511A (en) Small molecule inhibitors of egfr and pi3k
EA201590359A1 (ru) Лечение ревматоидного артрита
MX2016016992A (es) Aptameros especificos de tlr-4 y usos de los mismos.
MX2016013323A (es) Uso medico de compuestos de artemisinina y agonistas de gefirina.
TW201613864A (en) Novel compounds
PH12019502693A1 (en) Heteroaromatic compounds as vanin inhibitors
BR112017006552A2 (pt) composições e métodos para inibir a atividade biológica de biomoléculas solúveis
DK3241551T3 (da) Farmaceutisk sammensætning til behandling af kræft, indeholdende lactatmetalsalt
JO3372B1 (ar) مشتقات 5-بنزيل إيزوكينولين لعلاج أمراض القلب والأوعية الدموية
BR112018008931A2 (pt) ?compostos para tratamento de distúrbios hipoproliferativos?
ES2571441A1 (es) Uso de moléculas que reducen los niveles de lipocalina-2 para la fabricación de un medicamento para el tratamiento de aneurisma aórtico abdominal (AAA)
IN2014CH00304A (es)
EA201792282A1 (ru) Способы лечения заболеваний

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 2571441

Country of ref document: ES

Kind code of ref document: B1

Effective date: 20170307

FD2A Announcement of lapse in spain

Effective date: 20240326